
INZY
Healthcare · Biotechnology · $258.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2025
EPS trend, 90 days to now · -30.4% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 12, 2025 | Time not confirmed | -0.36 | 0.00 | +100.0% |
| May 5, 2025 | Before the open | -0.36 | -0.44 | -22.2% |
| Mar 10, 2025 | Before the open | -0.37 | -0.42 | -12.5% |
| Nov 5, 2024 | Before the open | -0.44 | -0.39 | +11.4% |
| Aug 6, 2024 | Before the open | -0.39 | -0.44 | -12.8% |
| May 7, 2024 | Before the open | -0.36 | -0.38 | -5.6% |
| Mar 12, 2024 | Before the open | -0.32 | -0.33 | -3.1% |
| Nov 7, 2023 | Before the open | -0.32 | -0.29 | +9.4% |
| Aug 8, 2023 | Before the open | -0.43 | -0.35 | +18.6% |
| May 9, 2023 | Before the open | -0.45 | -0.40 | +11.1% |
| Mar 22, 2023 | Before the open | -0.45 | -0.42 | +6.7% |
| Nov 10, 2022 | Before the open | -0.43 | -0.38 | +11.6% |
| Aug 15, 2022 | Before the open | -0.48 |
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving…
| -0.38 |
| +20.8% |
| May 10, 2022 | Before the open | -0.82 | -0.71 | +13.4% |
| Mar 15, 2022 | After the close | -0.68 | -0.79 | -16.2% |
| Nov 9, 2021 | After the close | -0.61 | -0.60 | +1.6% |
| Aug 11, 2021 | Before the open | -0.57 | -0.53 | +7.0% |
| May 12, 2021 | Before the open | -0.54 | -0.47 | +13.0% |
| Mar 25, 2021 | Before the open | -0.55 | -1.01 | -83.6% |
| Nov 12, 2020 | Before the open | -0.51 | -1.55 | -203.9% |
| Sep 3, 2020 | After the close | -1.41 | -7.57 | -436.9% |
| Jun 3, 2020 | Time not confirmed | -0.69 | -0.86 | -24.6% |